EBRT with or without STAD showed similar 15-year PCSS and OS rates in IRPC patients, with high PSA failure rates observed. Multivariate analysis indicated greater side effects in the STAD group ...

An investigator presented extended follow-up data from a phase 3 trial on aglatimagene besadenovec (CAN-2409) + prodrug in combination with standard-of-care EBRT in men with localized prostate cancer.

Adjuvant EBRT after RP may prolong biochemical PFS and MFS but not OS in patients with positive surgical margins, extracapsular extension, or seminal vesicle invasion, supporting a shared ...

Long-term results from a phase 3 study showed that adding a focal boost to standard external beam radiotherapy (EBRT) improved 10-year biochemical disease-free survival (DFS) and reduced biochemical ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk prostate cancer treated with external-beam radiation therapy (EBRT), ...

Adding supplemental external beam radiotherapy (EBRT) did not improve outcomes in higher-risk cancer patients who had brachytherapy, according to the long-term results of two trials. Specifically, ...

CHICAGO -- An investigational viral immunotherapy (CAN-2409; aglatimagene besadenovec) combined with a prodrug improved disease-free survival (DFS) when added to standard curative-intent radiotherapy ...

Trends in bladder cancer mortality: The influence of tobacco use and sociodemographic factors in the United States over two decades. Multimodal artificial intelligence (MMAI) model to identify benefit ...